Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-05-31T13:19:32.638Z Has data issue: false hasContentIssue false
  • English
  • Français

Olanzapine and its use for methamphetamine-induced psychosis

Published online by Cambridge University Press:  01 September 2022

S. Nazir ,
A. Talpur ,
N. Hassan  and
U. Sharif
S. Nazir*
Affiliation:
Texas Tech University Health Sciences Center, Psychiatry, Lubbock, United States of America
A. Talpur
Affiliation:
University of Louisville, Psychiatry, Louisville, United States of America
N. Hassan
Affiliation:
Bronxcare Health System, Psychiatry, Newyork, United States of America
U. Sharif
Affiliation:
Berkshire Medical Center, Psychiatry, Pittsfield, United States of America
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Over time the prevalence of methamphetamine associated psychosis (MAP) has increased globally including Asia and Europe. Shoptaw et al looked at an RCT and concluded that olanzapine is superior to haloperidol in terms of tolerability and the side effect profile as it causes fewer extrapyramidal symptoms. Another study by Xue et al compared the efficacy of olanzapine and haloperidol and found that they had comparable effects but the onset time in the olanzapine group was significantly earlier than the haloperidol group. Srisurapanont et al analyzed 6 RCTs and concluded that quetiapine and olanzapine are probably superior than aripiprazole and risperidone.

Objectives

The purpose of this review is to find out if olanzapine is better than other antipsychotics in treating methamphetamine-induced psychosis.

Methods

PubMed, SCOPUS, and Web of Science literature databases were screened and filtered by using specific search terms, inclusion/exclusion criteria. Texts of the selected articles and trials were reviewed and the search terms generated a total of 248 results from the databases. After applying the criteria 200 citations were left and 15 papers were reviewed.

Results

The literature review concluded that olanzapine can be used as an effective treatment for methamphetamine-induced psychosis. Olanzapine can help to reduce the psychotic symptoms in MAP with a quicker onset and lesser side effects.

Conclusions

Olanzapine can help in the treatment of methamphetamine-associated psychosis and can be considered as the first-line therapy. Research is further needed with a higher pool of candidates in the future to compare the efficacy and tolerability of different typical and atypical antipsychotics.

Disclosure

No significant relationships.

Keywords

PsychosisMethamphetamineMethamphetamine induced psychosisOlanzapine
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S718
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.